Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Newark Beth Israel Medical Center100 enrolled

Overview

Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

100

Conditions

Smoking Acute Coronary Syndrome

Interventions

Varenicline 100 mg by mouth twice dailyDRUG

this is an active drug to help smoking cessation

controlDRUG

this is the placebo that will help us maintain a blinded study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * active smokers presenting to hospital with an acute coronary syndrome Exclusion Criteria: * patients with an acute coronary syndrome who are not active smokers

Locations (1)

Newark Beth Israel Medical Center

Newark, New Jersey, United States

RECRUITING

Outcomes

Primary Outcomes

nicotine levels

Time frame: 1 month

Secondary Outcomes

recurrent myocardial ischemia

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.